A Multicenter, Prospective, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study of BB3 to Reduce the Severity of Delayed Graft Function in Recipients of a Deceased Donor Kidney
Phase of Trial: Phase III
Latest Information Update: 13 Jun 2017
At a glance
- Drugs BB 3 (Primary)
- Indications Delayed graft function
- Focus Registrational; Therapeutic Use
- Acronyms GIFT
- Sponsors Angion Biomedica
- 17 Jan 2017 Planned End Date changed from 1 Oct 2017 to 1 May 2018.
- 17 Jan 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jun 2017.
- 18 Feb 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.